XM không cung cấp dịch vụ cho cư dân của Mỹ.
G
G

Gilead


Tin tức

Biotech M&A to show less 'fire power' in 2024 due to low-valued deals

LIVE MARKETS-Biotech M&A to show less 'fire power' in 2024 due to low-valued deals Main U.S. indexes red; Dow off most, down ~0.8% Real Estate weakest S&P sector; Tech sole gainer Dollar up; crude gains ~2%; gold ~flat; bitcoin down ~2.5% U.S. 10-Year Treasury yield jumps to ~4.18% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
A
B
G
P
V
U
U

Gilead falls on withdrawing bladder cancer drug in US

BUZZ-Gilead falls on withdrawing bladder cancer drug in US ** Drugmaker Gilead's GILD.O shares fall 1% to $86.48 premarket ** Company says it is voluntarily withdrawing its drug Trodelvy for previously treated patients with a type of bladder cancer after consultation with U.S. FDA ** Trodelvy was granted accelerated approval for metastatic urothelial cancer in 2021 by the FDA and continued approval was dependent on results of a confirmatory trial ** The drug failed to improve survival for patien
G

Gilead withdraws bladder cancer drug in US after failed trial

UPDATE 2-Gilead withdraws bladder cancer drug in US after failed trial Adds trial details and context in paragraphs 5-6, 8-11 Oct 18 (Reuters) - Gilead Sciences GILD.O said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial. The decision was made in consultation with the U.S.
G

U.S. Abbott, Gilead, Roku

U.S. RESEARCH ROUNDUP-Abbott, Gilead, Roku Oct 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Abbott, Gilead and Roku, on Thursday. HIGHLIGHTS * Abbott ABT.N : JP Morgan raises target price to $135 from $125 * AIG AIG.N : JP Morgan raises to overweight from neutral * Gilead GILD.O : Raymond James raises target price to $95 from $94 * Lendingclub Corp LC.N : KBW raises to outperform from market perform * Roku Inc R
A
C
G
P
C
I
S
A
G
H
P
U

U.S. Aflac, Lincoln National, Prudential Financial

U.S. RESEARCH ROUNDUP-Aflac, Lincoln National, Prudential Financial Oct 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aflac, Lincoln National and Prudential Financial, on Wednesday. HIGHLIGHTS * Aflac Inc AFL.N : TD Cowen initiates coverage with hold rating; price target $102 * Corebridge Financial Inc CRBG.N : TD Cowen initiates coverage with buy rating * Lincoln National Corp LNC.N : TD Cowen initiates coverage
A
B
G
H
N
P
S
S
S
A
V
A
A
E
G
L
M

US ships Marburg vaccines to Rwanda after 11 die in outbreak

US ships Marburg vaccines to Rwanda after 11 die in outbreak By Philbert Girinema and Chandni Shah KIGALI, Oct 5 (Reuters) - The United States government completed an initial shipment of vaccine doses and therapeutic drugs for Marburg disease to Rwanda on Oct. 4, Thierry Roels, U.S. CDC Country Director in Rwanda told Reuters on Saturday. The U.S. government is also working closely with international partners and Rwanda's ministry of health on the start of clinical trials to evaluate investigati
G

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

UPDATE 1-Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Adds details in paragraph 2, background in paragraphs 4-6 Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus outbreak.
G

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak. Reporting by Mariam Sunny in Bengaluru' Editing by A
G

Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda

BRIEF-Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda Oct 3 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD DONATES REMDESIVIR FOR EMERGENCY USE IN RESPONSE TO MARBURG VIRUS DISEASE IN RWANDA GILEAD - IT WILL DONATE APPROXIMATELY 5,000 VIALS OF REMDESIVIR TO RWANDA MEDICAL SUPPLY Furth
G

Rwanda to start vaccine trials for Marburg disease in a few weeks

UPDATE 3-Rwanda to start vaccine trials for Marburg disease in a few weeks Adds detail from WHO in paragraphs 5-6, 8 By Philbert Girinema KIGALI, Oct 3 (Reuters) - Rwanda w ill start cinical trials of experimental vaccines and t reatments f or Marburg disease in the next few weeks , its health minister said on Thursday, t o fight the country's first outbreak of the viral fever, which has so far killed 11 people .
G

New York Times business news - Oct 3

PRESS DIGEST- New York Times business news - Oct 3 Oct 3 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - OpenAI, the company behind ChatGPT, said it had completed a $6.6 billion fund-raising deal that nearly doubles the high-profile company's valuation from just nine months ago.
G
M

Indian shares set to open lower, tracking Asian peers

INDIA STOCKS-Indian shares set to open lower, tracking Asian peers Oct 3 (Reuters) - Indian shares are likely to open lower on Thursday, tracking other Asian peers, as investors curb their risk appetite amid an escalation of the Middle East conflict. The GIFT Nifty GIFc1 was trading at 25,701.50 points as of 8:13 a.m. IST, indicating that the NSE Nifty 50 .NSEI will open below its previous close of 25,796.90. Worries of a further escalation in the Middle East intensified after Iran fired ballist
G
U
J

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries Oct 2 (Reuters) - Gilead Sciences GILD.O said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries. The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such as Botswana, Ethiopia and Kenya, until t
G

EU withdraws marketing authorisation for Abbvie's hepatitis C drug

UPDATE 2-EU withdraws marketing authorisation for Abbvie's hepatitis C drug Adds background in paragraphs 5 to 7 Oct 1 (Reuters) - The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's ABBV.N hepatitis C drug Exviera at the request of the company. The regulator said it withdrew the authorisation on Sept.
G

Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding

UPDATE 3-Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding Adds comments from CEO interview in paragraphs 4 and 8 By Niket Nishant Oct 1 (Reuters) - Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.
G

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Sept 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Sep-2024 AMC POCI.O Precision Optics Corporation Inc Q4 2024 Precision Optics Corporation Inc Earnings Release 30-Sep-2024 AMC TRAK Repositrak Inc Q4 2024 Park City Group Inc Earnings Release 30-Sep-2024 10:30 ENS EnerSys EnerSys Tech Talk: Lithi
G
N
P
U
L
M

FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial

BRIEF-FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Sept 23 (Reuters) - FDA: FDA: GILEAD ISSUES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF VEKLURY (REMDESIVIR) FOR INJECTION 100 MG/VIAL DUE TO THE PRESENCE OF A GLASS PARTICLE FDA: GILEAD PRODUCT RECALLED IS LYOPHILIZED FORM OF VEKLURY FOR INJECTIO
G

U.S. STOCKS Unity Software, Viking Holdings, Adobe

BUZZ-U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed in choppy trading on Thursday after higher-than-expected producer prices data kept a smaller 25-basis point rate cut by the Fed firmly on the table, while Moderna slumped following a downbeat revenue forecast.
A
G
K
M
U
U
U
D
A

U.S. STOCKS Gold miners, silver miners, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.
G
K
M
U
U
D
W
A

Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada

BUZZ-Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada ** Shares of drugmaker Gilead GILD.O rise nearly 2% to $82.55 ** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial ** The study included cisgender men, transgender men, tra
G



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.